The Filing Desk

Korro Bio vs X4 Pharmaceuticals

Korro Bio KRRO · X4 Pharmaceuticals XFOR · Biotechnology

X4 Pharmaceuticals reported revenue of $6 million in fiscal 2025, about the same as Korro Bio's $6 million in fiscal 2025. Korro Bio's revenue grew 181.5% in its latest year, and X4 Pharmaceuticals' grew 150.0%. Korro Bio had an operating margin of -1906.4%, against -1336.7% at X4 Pharmaceuticals. Free cash flow was −$79 million at Korro Bio and −$86 million at X4 Pharmaceuticals.

Side by side

Korro BioX4 Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$6M$6M
Revenue growth181.5%150.0%
Revenue growth a year, last 5 years−29.6%16.7%
Gross margin—11.4%
Operating margin−1,906.4%−1,336.7%
Net margin−1,834.5%−1,218.5%
Free cash flow−$79M−$86M
Free cash flow margin−1,237.2%−1,317.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count5.3%531.0%
Last close$12.19$2.96
P/E at the last close——
Insider trades, last 12 monthsbought $2.4 million, sold $5.7 millionsold $428,889
Piotroski F-score—3 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Korro BioX4 Pharmaceuticals
Operating margin
Percent of revenue
Korro BioX4 Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Korro BioX4 Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Korro Bio and X4 Pharmaceuticals pages.